Indivior PLC reported strong Q3 2025 results with a 15% increase in SUBLOCADE sales, driving a 2% rise in total net revenue, and raised full year guidance on adjusted EBITDA growth.

• Adjusted EBITDA grew 14% year-over-year, reflecting improved operational efficiency.
• Raised full year 2025 revenue guidance, projecting a 10% increase in SUBLOCADE net revenue.
• Implemented $150 million in annual cost reductions through organizational simplification and strategic focus.
• Continued stability observed in SUBOXONE Film pricing in the U.S.
• Solid unit dispense growth of 8% for SUBLOCADE, underscoring effective commercial execution strategies.